Login to Your Account



But Analysts Predict Approval Delay

Panel for Xenoport's RLS Drug Less Likely; Pain Data Positive

By Donna Young


Friday, September 18, 2009
Investors where fired up Thursday after XenoPort Inc. reported top-line Phase IIb results showing that its gabapentin prodrug significantly reduced neuropathic pain associated with post-herpetic neuralgia (PHN) in adults, driving shares up 25.6 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription